Experimental drug delays type 1 diabetes onset in mid-stage trial

(Reuters Health) - In people at high risk for type 1 diabetes, 14 days of therapy with the experimental drug teplizumab delayed development of the disease by a year or more, according to results from a mid-stage study presented Sunday.